주식/증권
📉 부정적
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
요약
bioAffinity's CyPath Lung sales momentum is gaining traction, but wider losses, funding needs and regulatory risks keep pressure on the stock.